TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2023 Earnings Call Transcript

Operator: Thank you. That is all the time we have for questions today. I would now like to turn the call back over to Mike Weiss for any closing comments.

Mike Weiss: Great. Thank you. So, again, as I believe you’ve heard today, we are quite pleased with the launch to date. We remain confident that BRIUMVI offers patients a differentiated CD20 option in a growing class. We believe the BRIUMVI profile, along with the convenient one-hour infusion administered twice a year at the lowest price of any branded MS treatment, together affirm our belief that BRIUMVI has the best-in-class potential. I want to thank everyone at TG for a fabulous effort. In addition to the commercial and medical teams that are on the front lines, our clinical, regulatory, safety, manufacturing, supply chain, quality, legal and compliance, and finance teams, have all performed at the highest levels to make this early launch possible. Everyone at TG remains committed to serving the MS community. And everything we do, we do with the focus on improving the lives of those living with MS. Thanks again for joining us today, and have a great day.

Operator: Thank you. That does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.